Skip to main content

Table 2 Median BCVA at each visit

From: Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings

BCVA

Time point

Pre ranibizumab

6 m pre switch

3 m pre switch

Baseline (switch)

3 m post switch

6 m post switch

9 m post switch

12 m post switch

Median (IQR) BCVA in letters

66 (58–74)

70 (62–77)

74 (64–77)

69 (62–74)

73 (64–77)

73 (61–78)

73 (65–77)

71 (59–77)

n

54

54

54

57

57

56

55

57

Statistical significance

ns

ns

**

 

***

**

***

ns

p value

0.3614

0.3314

0.0051

 

0.0006

0.0042

0.0006

0.066

BCVA

Time point

15 m post switch

18 m post switch

21 m post switch

24 m post switch

27 m post switch

30 m post switch

33 m post switch

36 m post switch

Median (IQR) BCVA in letters

71 (61–75)

73 (62–75)

69 (61–75)

70 (60–74)

71 (59–75)

71 (65–75)

71 (65- 78)

70 (64–77)

n

56

57

57

57

54

57

53

57

Statistical significance

ns

*

ns

ns

ns

ns

ns

ns

p value

0.0972

0.0444

0.4118

0.5681

0.8975

0.1288

0.143

0.3168

  1. Best corrected visual acuity (BCVA) before the initiation of treatment with ranibizumab, 6 and 3 months before the switch to aflibercept, at the day of the decision to switch and every 3 months after the switch up to 36 months follow-up. BCVA was significantly improved compared to baseline 3 months pre switch, 3, 6, 9 and 18 months post switch (Wilcoxon matched-pairs signed rank test)
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us